Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Metrics to compare | NWBO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNWBOPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.5x | −2.7x | −0.6x | |
PEG Ratio | −0.46 | −0.04 | 0.00 | |
Price/Book | −3.8x | 2.4x | 2.6x | |
Price / LTM Sales | 344.2x | 6.9x | 3.3x | |
Upside (Analyst Target) | - | 334.8% | 40.1% | |
Fair Value Upside | Unlock | 5.1% | 5.3% | Unlock |